Seattle Genetics ' ' Refreshing ' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out

handily beat Wall Street's fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock hit a five-month high. X Analysts were impressed by Seattle Genetics' enthusiasm for its cancer treatment, Padcev. Guidance for full-year sales excluded the likelihood Padcev…#alks #sgen #seattlegenetics #marketsmithcom #svbsecurities #andrewberens #tukysa #astrazeneca #daiichisankyo #rbccapitalmarkets
Source: Reuters: Health - Category: Consumer Health News Source Type: news